CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Abbisko Medicine Co., Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Abbisko Medicine Co., Ltd.
Huan Ke Lu 515Hao 1Hao Lou 12BCeng
Phone: +86 2168912098p:+86 2168912098 SHANGHAI, SHA  201210  China Ticker: 22562256
Business Summary
Abbisko Medicine Co., Ltd., formerly Abbisko Cayman Limited, is a pharmaceutical company committed to the discovery, research and development of innovative and differentiated medicines. The Company owns a pipeline of program candidates, with a primary focus on oncology. The Company’s pimicotinib (ABSK021) for the treatment of tenosynovial giant cell tumor (TGCT) is commercially launched in China, and several other candidates are in clinical development stages. ABSK011 is a small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). The Company’s products are primarily developed for hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), urothelial cancer (UC), gastric cancer (GC) and other solid tumors.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Chief Executive Officer, Co-Founder Yao-ChangXu 66 6/10/2021 3/28/2018
Co-Founder, Senior Vice President, Executive Director HongpingYu 57 3/2/2026 3/28/2018
Group Chief Financial Officer, Head - Strategic Operations LinYe 54 4/28/2022 11/9/2020
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 286 (As of 6/30/2026)
Outstanding Shares: 716,077,350 (As of 10/30/2026)
Stock Exchange: HKG


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026